#今日行业热点#

①The New England Journal of Medicine：Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid

临床试验：重组人源化抗甲状腺素运载蛋白淀粉样变（ATTR）抗体NI006用于去除心脏ATTR以改善心功能障碍的Ⅰ期临床数据

DOI: 10.1056/NEJMoa2303765

②The New England Journal of Medicine：Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

临床试验：全人源单克隆抗体度匹鲁单抗（Dupilumab）用于嗜酸性粒细胞计数提示的2型炎症的慢性阻塞性肺疾病(COPD)

DOI: 10.1056/NEJMoa2303951

③The New England Journal of Medicine：Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma

临床试验：人源化IgG1单克隆抗体Peresolimab用于成人类风湿关节炎的Ⅱ期试验

DOI: 10.1056/NEJMoa2209856

④Journal of Thoracic Oncology：Clinical benefit from immunotherapy in patients with small cell lung cancer is associated with tumor capacity for antigen presentation

小细胞肺癌(SCLC)患者对免疫检查点阻断(ICB)应答与肿瘤抗原呈递能力相关

DOI: 10.1016/j.jtho.2023.05.008

⑤Journal of Translational Medicine：CEBPG suppresses ferroptosis through transcriptional control of SLC7A11 in ovarian cancer

CEBPG通过转录调控SLC7A11抑制卵巢癌(OC)细胞铁死亡的内在机制

DOI: 10.1186/s12967-023-04136-0

⑥Breast Cancer Research and Treatment：Classification of breast tumors by using a novel approach based on deep learning methods and feature selection

观点：一种基于深度学习和特征选择的乳腺肿瘤分类方法

DOI: 10.1007/s10549-023-06970-8

⑦全球新靶点的强效及选择性单克隆抗体(mAb)LAE102针对实体瘤的I/II期临床研究（IND）获FDA批准

⑧国内首个靶向 Nectin-4 ADC 创新药9MW2821 的临床前研究成果发表，结构更稳定，安全性更佳

⑨有望用于降糖、减肥、代谢综合征等多种代谢性疾病的长效GLP-1类创新结构多肽药物RAY1225Ⅰ期临床试验完成首例受试者入组

⑩抗体-细胞因子融合蛋白SHR-2001获国家药品监督管理局批准用于系统性红斑狼疮适应症临床试验

科学探索的世界充满挑战，AtaGenix致敬每一位拓荒者，更致力于成为您信赖的合作伙伴！